Nan Fung Trinity HK Ltd. Invests $10.18 Million in Savara Inc. $SVRA

Nan Fung Trinity HK Ltd. acquired a new stake in shares of Savara Inc. (NASDAQ:SVRA) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,688,500 shares of the company’s stock, valued at approximately $10,182,000.

Other large investors have also recently added to or reduced their stakes in the company. VR Adviser LLC boosted its stake in shares of Savara by 42.7% during the 3rd quarter. VR Adviser LLC now owns 12,681,043 shares of the company’s stock valued at $45,271,000 after buying an additional 3,796,780 shares during the period. Vanguard Group Inc. increased its stake in shares of Savara by 20.8% in the fourth quarter. Vanguard Group Inc. now owns 10,041,647 shares of the company’s stock worth $60,551,000 after acquiring an additional 1,728,453 shares during the last quarter. Nantahala Capital Management LLC raised its holdings in shares of Savara by 5.4% during the third quarter. Nantahala Capital Management LLC now owns 8,775,375 shares of the company’s stock worth $31,328,000 after acquiring an additional 450,000 shares in the last quarter. Rosalind Advisors Inc. raised its holdings in shares of Savara by 50.7% during the third quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock worth $14,280,000 after acquiring an additional 1,345,056 shares in the last quarter. Finally, Swedbank AB boosted its position in Savara by 54.5% during the fourth quarter. Swedbank AB now owns 850,000 shares of the company’s stock valued at $5,126,000 after purchasing an additional 300,000 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Trading Up 1.4%

Savara stock opened at $5.23 on Friday. Savara Inc. has a one year low of $1.89 and a one year high of $7.01. The company’s fifty day moving average price is $5.43 and its two-hundred day moving average price is $5.45. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.85 and a quick ratio of 11.85. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -9.87 and a beta of 0.28.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Friday, March 13th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). On average, analysts forecast that Savara Inc. will post -0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on SVRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Savara in a report on Monday, March 16th. Oppenheimer started coverage on Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price objective on the stock. William Blair set a $10.00 price objective on shares of Savara in a research report on Monday, March 16th. Finally, Wall Street Zen cut shares of Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Savara has an average rating of “Moderate Buy” and an average price target of $9.13.

Savara Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.